Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announces that it has completed the acquisition of its long-standing partner Endospan Ltd. (“Endospan”), a pioneer in the endovascular repair of aortic arch disease and developer of the NEXUS® Aortic Arch System. Artivion utilized its previously drawn $150 million delayed draw term loan to fund the $135 million upfront net purchase price for Endospan. The U.S. Food and Drug Administration (FDA) approved the premarket approval application (PMA) for the NEXUS branched endovascular stent graft system in April 2026. Artivion has acted as the exclusive distributor of the NEXUS System across EMEA since 2019.
Read the full article: Artivion Completes Acquisition of Endospan Ltd. //
Source: https://www.prnewswire.com/news-releases/artivion-completes-acquisition-of-endospan-ltd-302774254.html